Sherbrooke Park Advisers LLC Cuts Stake in Elanco Animal Health Incorporated (NYSE:ELAN)

Sherbrooke Park Advisers LLC lowered its holdings in shares of Elanco Animal Health Incorporated (NYSE:ELAN) by 67.4% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 18,631 shares of the company’s stock after selling 38,456 shares during the quarter. Sherbrooke Park Advisers LLC’s holdings in Elanco Animal Health were worth $226,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in the business. Nomura Holdings Inc. purchased a new stake in shares of Elanco Animal Health during the fourth quarter worth about $177,000. Meridiem Capital Partners LP purchased a new stake in shares of Elanco Animal Health during the fourth quarter worth about $4,547,000. Lazard Asset Management LLC grew its position in shares of Elanco Animal Health by 644.3% during the fourth quarter. Lazard Asset Management LLC now owns 29,006 shares of the company’s stock worth $350,000 after purchasing an additional 25,109 shares in the last quarter. Jefferies Financial Group Inc. purchased a new stake in shares of Elanco Animal Health during the fourth quarter worth about $980,000. Finally, Gotham Asset Management LLC grew its position in shares of Elanco Animal Health by 41.0% during the fourth quarter. Gotham Asset Management LLC now owns 477,768 shares of the company’s stock worth $5,786,000 after purchasing an additional 138,812 shares in the last quarter. Hedge funds and other institutional investors own 97.48% of the company’s stock.

Analyst Upgrades and Downgrades

ELAN has been the subject of several research analyst reports. Morgan Stanley cut their price target on Elanco Animal Health from $14.00 to $13.00 and set an “equal weight” rating for the company in a report on Wednesday, February 26th. Barclays cut their price target on Elanco Animal Health from $20.00 to $19.00 and set an “overweight” rating for the company in a report on Wednesday, February 26th. Piper Sandler cut their price target on Elanco Animal Health from $16.00 to $12.00 and set a “neutral” rating for the company in a report on Thursday, March 6th. Stifel Nicolaus raised their price target on Elanco Animal Health from $15.00 to $16.00 and gave the company a “buy” rating in a report on Monday. Finally, UBS Group cut their price target on Elanco Animal Health from $18.00 to $17.00 and set a “buy” rating for the company in a report on Wednesday, February 26th. Four analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $15.17.

Elanco Animal Health Stock Performance

NYSE ELAN opened at $13.08 on Wednesday. The stock has a market capitalization of $6.50 billion, a PE ratio of 32.70, a P/E/G ratio of 2.50 and a beta of 1.49. The company has a debt-to-equity ratio of 0.66, a current ratio of 2.55 and a quick ratio of 1.31. The business has a 50 day simple moving average of $10.22 and a two-hundred day simple moving average of $11.45. Elanco Animal Health Incorporated has a 1-year low of $8.02 and a 1-year high of $18.80.

Elanco Animal Health (NYSE:ELAN) last announced its earnings results on Wednesday, May 7th. The company reported $0.37 EPS for the quarter, topping analysts’ consensus estimates of $0.31 by $0.06. The firm had revenue of $1.19 billion during the quarter, compared to analysts’ expectations of $1.17 billion. Elanco Animal Health had a return on equity of 6.78% and a net margin of 4.60%. The company’s quarterly revenue was down 1.0% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.34 EPS. On average, research analysts predict that Elanco Animal Health Incorporated will post 0.91 EPS for the current fiscal year.

Insider Transactions at Elanco Animal Health

In related news, Director Lawrence Erik Kurzius bought 10,000 shares of the company’s stock in a transaction dated Tuesday, March 11th. The stock was purchased at an average price of $10.20 per share, for a total transaction of $102,000.00. Following the acquisition, the director now owns 111,459 shares in the company, valued at $1,136,881.80. This trade represents a 9.86% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. Company insiders own 0.89% of the company’s stock.

Elanco Animal Health Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.